Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Operating Expenses for 9 consecutive years, with $231.6 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 1249.32% to $231.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $311.3 million through Dec 2025, up 304.26% year-over-year, with the annual reading at $109.0 million for FY2025, 41.56% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $231.6 million at Ultragenyx Pharmaceutical, up from $28.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $231.6 million in Q4 2025, with the low at $3.1 million in Q2 2021.
  • Average Other Operating Expenses over 5 years is $23.9 million, with a median of $11.4 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses plummeted 93.86% in 2021, then surged 1249.32% in 2025.
  • Over 5 years, Other Operating Expenses stood at $3.5 million in 2021, then surged by 51.58% to $5.3 million in 2022, then surged by 122.64% to $11.8 million in 2023, then skyrocketed by 44.96% to $17.2 million in 2024, then soared by 1249.32% to $231.6 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $231.6 million, $28.0 million, and $23.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.